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Reticulons (RTNs) are a group of membrane proteins localized on the ER and known to regulate ER structure and functions.
Several studies have suggested that RTNs are involved in diﬀerent important cellular functions such as changes in calcium
homeostasis, ER-stress-mediated cell death, and autophagy. RTNs have been demonstrated to exert a cancer speciﬁc proapoptotic
function via the interaction or the modulation of speciﬁc proteins. Reticulons have also been implicated in diﬀerent signaling
pathways which are at the basis of the pathogenesis of several neurodegenerative diseases. In this paper we discuss the
accumulating evidence identifying RTN-1C protein as a promising target in the treatment of diﬀerent pathologies such as cancer
or neurodegenerative disorders.
1.Introduction
Neuronal death occurs by necrosis or apoptosis, which diﬀer
morphologically and biochemically. Necrosis is the result of
extreme perturbation of the cellular environment, as occurs
in ischemic insults or trauma. In contrast apoptosis is
dependent on intracellular pathways which lead to cellular
commitment to a deﬁned series of steps leading to cell
suicide. Apoptosis is an important mechanism in normal cell
turnover and in growth and development, as well as in aging.
Alterationofthismachineryresultsintheevolutionofcancer
and autoimmune or degenerative diseases. The process of
neuronalapoptosisinvolvestwoprincipalpathwaysthatcon-
vergeonactivationofcaspases:thecellsurfacedeathreceptor
pathway and the mitochondrial pathway [1] .H o w e v e r ,ar o l e
in the initiation of neuronal apoptotic cell death by other
organelles, including endoplasmic reticulum (ER), is now
well established [2].
Disruption of ER homeostasis interferes with protein
folding and leads to the accumulation of unfolded and mis-
folded proteins in the ER lumen. This condition, designated
“ER stress,” can be triggered by stimuli that perturb ER
function, including depletion of Ca2+ stores, reduction of
disulphide bonds, overexpression of certain proteins, and
nutrient/glucose deprivation [3]. To maintain homeostasis,
the ER mounts an unfolded protein response (UPR), as a
self-protective mechanism, which results in transcriptional
induction of UPR genes, translational attenuation of global
protein synthesis, and ER-associated protein degradation
(ERAD) [3]. However, if these adaptive responses are not
suﬃcient to relieve the ER stress, the cell dies through
apoptosis[3].Interestingly,prolongedERstressisatthebasis
of the pathogenesis of several neuronal disorders [4, 5]. In
fact,recentstudieshavereportedthatmanyhumandisorders
have their origin from dysfunctions in the endoplasmic
reticulum and that regulation of some important UPR
mediators may be potential targets for modulating ER stress
response [6].
For example, ER-stress-dependent apoptosis is impor-
tantinischemia-reperfusioninjuryandinneurodegenerative
diseases (such as Alzheimer’s and Parkinson’s), where abnor-
malities have been identiﬁed in protein folding or secretion
in the Golgi-ER compartment [4].
In the last few years a new family of proteins, reticulons
(RTN), primarily localized on the ER membrane, has
attracted particular interest due to their implication in
diﬀerent cellular processes [7]. They play important role in
bending and shaping the ER membrane, in traﬃcking of2 International Journal of Cell Biology
materialfromtheERtotheGolgiapparatus,andinapoptosis
[8–10]. In particular, studies from diﬀerent groups have
indicated that RTN proteins show a proapoptotic function
mediated by the induction of endoplasmic reticulum stress
[11, 12]a n da l s oa c ta sk e yr e g u l a t o r so fE Rm o r p h o l o gya n d
nuclear envelope formation [13].
The mammalian reticulon family of proteins consists of
four members (RTN1–RTN4); the speciﬁc functions for
most of them are presently poorly understood although
RTN4(alsocalledNogo)hasbeenwidelydemonstratedtobe
an inhibitor of axonal extension and neurite outgrowth [14].
RTN genes are expressed as multiple N-terminal isoforms
that are generated by the use of diﬀerent promoters or
alternative splicing events [15]. Their C-terminal reticulon
domain is evolutionarily conserved while the speciﬁcity of
the N-terminal region contributes to their interaction with a
vast array of proteins [16–19]. Although the reticulon genes
are expressed in many tissues and are conserved in diﬀerent
phyla, suggesting a basic function in cell physiology and
a universal role in the eukaryotic system, some of them
(RTN-1A, RTN-1C, Nogo-A and RTN-2) are preferentially
expressed in nervous tissues [20].
Reticulonswereoriginally identiﬁed asmarkersforcarci-
nomas with neuroendocrine characteristics [21]. In particu-
lar, the reticulon family gene 1 (RTN-1) was characterized by
antibodies that stained a subset of neuroendocrine tissues
and neoplasms [21] and was formerly called neuroendo-
crine-speciﬁc protein.
There is no doubt that cellular homeostasis of RTNs is
important for normal cellular function. In particular, the
pattern of RTNs localization in the ER, Golgi, and plasma
membranestronglysuggeststheexistenceoftraﬃckingfunc-
tions in the secretory compartment. In line with this ﬁnding
it has been demonstrated that reticulons interact with several
proteins regulating endo- and exocytosis processes [22].
They also have been identiﬁed as proteins showing a
peculiar and almost exclusive localization to the tubular ER
[23]. Moreover they contain a domain of ∼200 amino acids
(RHD), including two hydrophobic segments of unusual
length (30–35 residues), which are thought to form a hairpin
in the membrane of endoplasmic reticulum [23]. These
structural properties, together with reticulons’ ability to
oligomerize, allow these proteins to generate and/or stabilize
tubules in vitro and to play a key role in the mechanism
by which the tubular network of the endoplasmic reticulum
is generated and maintained [23]. It has been also dem-
onstrated that reticulon proteins are deeply involved in
nuclear envelope formation during mitosis in metazoans by
achromatin-mediated reorganizationofthetubularER[13].
In fact, it has been suggested that the levels of reticulons
directly aﬀect the balance between tubules and sheets in the
ER and contribute to nuclear envelope formation [13].
On the other hand, more recent studies have expanded
the biological functions of RTNs in several neuronal disor-
ders [24–26], including cancer of cells of neuronal origin or
neurodegeneration pathologies such as Alzheimer’s disease
and amyotrophic lateral sclerosis (ASL) [27]. It has been also
demonstrated that reticulons participate in and regulate the
pathogenesis of other diseases such as atherosclerosis [28].
2.RTN-1C andBrain Tumors
Cancerischaracterizedbyanimbalancebetweencelldivision
and cell death, caused by homeostatic changes occurring
duringthetransformationprocess,theconsequenceofwhich
results in dysregulation of apoptosis. Diﬀerent therapeutic
approaches have been used to counteract tumors growth and
induce apoptosis, largely based on the induction of p53-
dependent DNA damage. However, since more than 50% of
tumors are defective in p53-family transcriptional activity,
with mutations resulting in abrogated protein function and
genetic instability, many tumors are insensitive to these
treatments, leaving an acute need for novel therapies able to
induceapoptosisindependentlyofp53.Thisneedisapparent
even in tumors lacking in (or with rare occurrence of) p53
mutations, such as neuroectodermal tumors, a family of
tumors notoriously resistant to apoptosis due to defective
activation of apoptotic signalling pathways mediating either
death receptor ligation or DNA damage [29–31]. Fur-
thermore, these tumors remain resistant to p53-dependent
damage despite p53 status being rarely mutated [32–34]a s
r e p o r t e df o rm a n yo t h e rt y p e so fc a n c e r[ 35]. The poor
response to chemotherapy thus results in poor survival rates,
leaving us in acute need of novel therapeutic strategies. It has
been suggested that inducing apoptosis via ER stress may
represent a novel way to kill cancer cells that are resistant
to apoptosis mediated by death-receptor ligation or DNA
damage [36].
Reticulons are expressed in most neuroendocrine tu-
mors; they are considered to be highly sensitive and speciﬁc
markers of neuroendocrine diﬀerentiation for use in the
diagnosis. In this context it is interesting that reticulons can
exert a cancer-speciﬁc proapoptotic function. Such evidence
is particularly pertinent for the RTN-1C family member.
The ﬁrst experimental results in this regard detected RTN-
1C capability of interacting with glucosylceramide synthase
(GCS) (Figure 2), a key enzyme in the biosynthesis of gly-
cosphingolipids,andimplicatedinmanybiologicalphenom-
ena, including multidrug resistance (MDR) [37]. Various
studies have demonstrated a direct correlation between the
development of MDR and increased levels of glucosylce-
ramide [37, 38], with GCS being suggested as a candidate
target for cancer therapy.
GCSinhibition,bybothantisenseandthespeciﬁcinhibi-
tor (D-threo)-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol (PDMP), results in a drastic decrease of apoptosis
inducedbythep53-independent chemotherapeuticagentN-
(4-hydroxyphenyl)retinamide (fenretinide) in neuroepithe-
lioma cells [39]. Signiﬁcantly it has been demonstrated that
RTN-1C not only interacts with GCS at Golgi/ER interface
but also modulates its catalytic activity in situ and aﬀects the
apoptotic response to fenretinide-induced apoptosis via a p-
53 independent mechanism [40].
Thus GCS role in fenretinide-induced apoptosis is inﬂu-
enced by RTN-1C, which provides a functional link between
Golgi and ER in this response. These results conﬁrmed the
possibilityofdevelopingatargetedtherapyforcancerusinga
combination of p53-dependent and p53-independent path-
ways. In line with this, we demonstrated that RTN-1CInternational Journal of Cell Biology 3
regulates in a mutually exclusive way ER stress versus
DNA-damage-induced cell death [11]. In fact, the increase
of RTN-1C protein levels per se results in endoplasmic
reticulum stress-induced cell death, mediated by an increase
of cytosolic Ca2+. This increase also signiﬁcantly sensitizes
cells to diﬀerent endoplasmic reticulum stress inducers [11].
In line with these ﬁndings, the reduction of RTN-1C, by
means of antisense DNA expression, reduced the response
to ER stressors [11]. In the presence of high RTN-1C levels,
genotoxic drugs become ineﬀective as a consequence of
the cytoplasm translocation of p53 protein; conversely the
silencing of endogenous RTN-1C boots the eﬀectiveness of
genotoxic drugs [11]. These data indicate that RTN-1C is
ableto modulate the cellularsensitivity to diﬀerent apoptotic
pathways and so it represents a promising molecular target
for new drug development.
Other interesting data provided by experiments demon-
strated that RTN-1C expression is directly correlated to cal-
reticulin (CRT) exposure on the plasma membrane; this is
through a mechanism mediated by the reduction of endo-
plasmic reticulum Ca2+ [41]. Such an event has been proved
to be important for the activation of anticancer immune
response and cell death. In fact, CRT exposure has been
correlated to immunogenic celldeath after anthracycline and
γ-radiation in mouse models and has the potential for ren-
dering conventional chemotherapies immunogenic [42, 43].
Morerecentlyithasbeenreportedthatthesyntheticpep-
tide corresponding to the C-terminal region (aa 179–208) of
the human RTN-1C is able to bind DNA. The C-terminus of
RTN-1C is characterized by the presence of an H4 histone
consensus motif [PS000047 HISTONE H4] (GAKRH) [44]
(Figure 1), the lysine present in this consensus sequence
being one of the four residues that can be acetylated and
modulate the H4 histone interaction with DNA [45].
Lysine acetylation is a reversible and highly regulated
posttranslational modiﬁcation, initially discovered on his-
tones, and known to regulate diverse protein properties in-
cluding DNA-protein interaction, subcellular localization,
transcriptionalactivityandproteinstability[46].Acetylation
modiﬁes the lysine residues of both histone and nonhistone
target proteins, such as p53, and is now recognized as an
important regulatory step in gene transcription. Moreover
lysine acetylation and its regulatory enzymes (acetyltrans-
ferases, HAT and deacetylases, HDAC) have been intimately
associated with many diﬀerent diseases, such as cancer and
neurodegenerative disorders [47, 48] and with diﬀerent
cellular functions including stress response and apoptosis
[49]. In this regard epigenetic regulation of gene tran-
scription has recently attracted wide interest in the ﬁeld
of cancer especially because several genes implicated in
oncogenesis are regulated by acetylation and deacetylation
[50]. Modiﬁcation of proteins by histone acetyltransferases
or histone deacetylases plays an important role in the
control of gene expression while their dysregulation has
been linked to malignant transformation and other diseases
[48]. Histone deacetylases are recognized as one of the
most promising targets for cancer treatment, many HDACs
inhibitors currently undergoing clinical trials [51, 52].
These enzymes are nowadays considered among the best
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Figure 1: (a) Scheme showing the reticulons distribution on endo-
plasmic reticulum and the physical connection between nuclear
envelope and ER membrane. (b) Schematic diagram of RTN-1C
and histone H4 proteins showing the shared GAKRH motif. The
blue aminoacids indicate the two hydrophobic segments of RTN-
1C protein. The red aminoacids indicate the three positive charges
in the H4 consensus motif. RTN-1C is acetylated on Lys 204.
potential targets for antineoplastic therapy [51]. HDACs are
overexpressed in many cancer cells, and the death-inducing
capability of diﬀerent HDAC inhibitors correlates with their
inhibitory potency. Interestingly thesecompounds havebeen
demonstrated to induce apoptosis mediated by caspase
activation as well as caspase-independent autophagic cell
death [53]. Induction of two modes of programmed cell
death by HDAC inhibitors indicates that these drugs might
beparticularlyvaluablewhentreatingcancerswithapoptotic
defects.
In particular, inhibition of HDACs results in growth
arrest and apoptosis of cancer cells while their deregulation
has been linked to autophagy induction [54], suggesting that
the epigenetic regulation of gene expression may be a fertile
area for the development of anti-cancer strategies.
As previously reported, an H4 histone consensus motif
has been identiﬁed in the C-terminal domain of RTN-1C.
All the three positively charged amino acids (KRH) in the
H4 consensus are essential for RTN-1C-mediated apoptosis.
The function of this reticulon protein has been shown4 International Journal of Cell Biology
to be modulated by posttranslational acetylation on lysine
204. Worth noting is a direct correlation between RTN-
1C acetylation and HDACs activities; in fact the reticulon
protein is able to negatively modulate their enzymatic
activity (Figure2). Moreover, RTN-1C protein is able to bind
to DNA, this interaction being regulated by the acetylation
process [45].
Considering the critical role of lysine acetylation in regu-
lating diverse cellular functions, such as cancer development
and human brain disorders [48, 51], HDAC substrates could
represent candidate proteins relevant to human disease and
therapeutic targets for drug design. In this context RTN-
1C not only represents an important candidate for the
development of new epigenetic therapeutic strategies, but
also a novel protein with aﬃnity for DNA, which could
regulate the interaction between the ER/nuclear envelope
membranes and chromatin.
3. RTN-1C andAutophagy
Another interesting connection between RTN-1C and cancer
development may be the reticulon possible involvement in
autophagy induction. Autophagic cell death is another
important physiological cell death process, involved in devel-
opment and stress responses. Furthermore, like apoptosis,
autophagic cell death is involved in tumorigenesis, even if
currently there is no cancer therapeutic approaches that
speciﬁcally target the autophagic cell death machine.
It is now well accepted that there is a complex interplay
between apoptosis and autophagy and that the molecular
regulators are interconnected; numerous death stimuli are
capableof activating either pathwayand both pathwaysshare
several genes that are critical for their respective execution
[55].Inparticular,severalreportshaveindicatedafunctional
link between ER stress signaling pathways and autophagy.
This is highlighted ﬁrstly by the possibility that endoplasmic
reticulum stress response may lead to the induction of
autophagy, and secondly by the fact that deregulation of
this process causes several disorders characterized by the
accumulation of toxic proteins in the ER [56]. The cross-talk
between apoptosis and autophagy is critical and represents
a key factor in the outcome of death-related pathologies
such as cancer, its development and treatment. In particular,
accumulating evidence suggests that ER stress is linked
to autophagy [57, 58], where inhibition of the apoptosis
pathway induces activation of the autophagy programme
and vice versa [55, 59]. Moreover it has been shown
that proper function of ER is required for autophagosome
formation;whentheERsensestheaccumulationofunfolded
misfolded protein, it can signal the induction of autophagy
to overcome the resulting stress [60]. Finally, the possibility
that autophagy could act as degradation system for unfolded
protein accumulated in the ER in addition to ERAD has been
demonstrated [61]. Interestingly a role for autophagy in the
prion disease process has recently been suggested. In this
regardit hasbeenreported thatcytoplasmic prion aggregates
lead to endoplasmic reticulum stress activation of reticulon
3, impairment of ubiquitin-proteasome system, induction of
RTN-1C
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Figure 2: Schematic representation of the diﬀerent RTN-1C-
induced signaling pathways. Modulation of RTN-1C expression
triggers the ER stress pathway and the regulation of diﬀerent
proteins (green ovals) at diﬀerent levels (blue boxes). These events
aﬀect cellular processes (red boxes) which are at the basis of several
human pathological settings (grey boxes).
autophagy, and apoptosis [62]. In this context it seems that
RTN3 negatively regulates autophagy.
IthasbeenalsosuggestedthatinducingapoptosisviaER-
stress and/or autophagy may represent a novel way to kill
chemoresistantcellsandapromisingapproachforenhancing
eﬃciency of cancer chemotherapy [37, 63]. Interesting pilot
data (manuscript submitted) show that in neuroblastoma
cells the modulation of RTN-1C expression disrupts Ca2+
signalling and induces Ca2+-dependent autophagy. We can
assume that autophagy may act as a prosurvival mechanism
in response to ER stress and the accumulation of unfolded
or misfolded proteins; thus autophagy machinery is perhaps
activated to degrade the UPR proteins. Conversely, when the
stress becomes severe and prolonged, these ﬁne regulatory
mechanismsarenotsuﬃcientandthecellundergoesapopto-
sis. According to this the upregulation of RTN1-C expression
results in ER stress induction, ﬁnally leading to apoptotic cell
death [11]. These data are a compelling reason to further
explore the role of RTN-1C in autophagy induction and
to understand to what extent and by which mechanism
ER-stressed cells escape autophagy protection and commit
apoptosis.
Future studies should deﬁne the molecular details dic-
tating the alternative behaviour of the diﬀerent RTN family
members in autophagy regulation.International Journal of Cell Biology 5
4. RTN-1C and Neurodegeneration
Another exciting frontier of reticulon research is the ﬁeld of
neurodegenerative diseases. It has been widely demonstrated
that the ER stress pathway is implicated in various neu-
rodegenerative pathologies [6]. For example UPR activation
has been shown to be an early event in the brain of
Alzheimer’s patients [64]. It has also been observed that
motoneurons of amyotrophic lateral sclerosis (ASL) patients
are characterized by ER alterations, so suggesting that the
UPR response is activated and that ER stress may be
involved in the neurodegeneration of these cells in early
stages of ASL [65] .I nt h i sc o n t e x t ,r e t i c u l o n sh a v eb e e n
shown to play an important role in the nervous system
both in normal and pathological settings, and recent studies
have expanded the biological functions of RTNs in several
CNS disorders, including Alzheimer’s disease (AD) [66–68].
The latter, AD, is a progressive neurodegenerative disorder
characterized by cognitive deﬁcits and extensive neuronal
loss. Several pathological changes have been described in
postmortem brains of AD patients, including beta-amyloid
(Abeta) plaques, intracellular neuroﬁbrillary tangles formed
by the hyperphosphorylated tau protein, inﬂammation, and
extensive cell death [69]. One of the earliest molecular
events in AD patients involves disturbances in calcium
homeostasis [70]. Interestingly, it was found that all four
human reticulon proteins can modulate BACE1 enzymatic
activity [71] thought to contribute to early synaptic loss
leadingtotheinitialcognitivedecline.Inparticular,reticulon
proteins block access of BACE1 to APP and reduce the
cleavage of this protein [72]. Thus, changes in the expression
of reticulon proteins in AD brain are likely to aﬀect cellular
Abeta and the formation of amyloid plaques in AD [71, 73].
Studies carried out on postmortem brain tissues have
revealed changes in reticulon expression in the temporal
and frontal cortex of patients with Alzheimer’s disease [74].
In particular, it has been demonstrated that the expression
of RTN-1C is signiﬁcantly reduced in the frontal cortex
of Alzheimer’s disease patients compared to controls [74].
Finally altered RTN expression has been directly correlated
to signiﬁcative eﬀects on cellular traﬃcking and abnormality
in exocytosis or endocytosis; these may represent one of the
mechanisms that could lead to neurodegenerative disorders
[75, 76].
Wehaverecentlyshown,bytheuseofmicroarrayanalysis
of the whole human genome, that RTN-1C is able to speciﬁ-
cally regulate gene expression, modulating transcript clusters
implicated in the onset of neurodegenerative disorders [77].
In vivo studies have also established that enhanced
expression of this reticulon family member in the cerebral
cortex results in ER stress, leading to a neurodegenerative
process characterized by an abnormal synaptic plasticity at
corticostriatal synapses [77].
Another important mechanism involved in neurodegen-
eration process is the regulation of calcium homeostasis. Dy-
namic changes in calcium concentration within the ER and
alteration of ER calcium homeostasis may be important in
regulation of cell function and survival and may trigger vari-
ous forms of neurodegeneration and/or neuropathy [78, 79].
In fact, disruption of the ER calcium homeostasis triggers ER
stress response, which in turn may trigger a cascade of events
leading to survival or death of neuronal cells.
Interestingly, RTN-1C modulates the expression of genes
which has been demonstrated to be aﬀected in schizophrenia
with a common thread related to Ca2+ signalling [80]. It has
been observed that schizophrenic patients displayed elevated
mobilization of Ca2+ from intracellular stores in response to
receptor stimulation; this suggests that increased cytosolic
calcium may be the primary molecular abnormality in this
pathology [81]. In keeping with this ﬁnding, it is known
that the reticulon protein controls cytosolic Ca2+ levels by
depleting the ER Ca2+ stores [11]. Matching these ﬁndings,
reticulon overexpression has been observed in the cortex of
patients aﬀected by diﬀerent neuronal pathologies including
schizophrenia [82]. Furthermore, numerous studies have
shown that the ER, whose function is strictly regulated
by RTN-1C, plays a number of essential roles in synaptic
transmission and plasticity at many central synapses [81].
Conversely, perturbation of ER Ca2+homeostasis is critically
involved in aberrant forms of synaptic plasticity in mouse
models of AD and schizophrenia [4, 83, 84]. In this context,
it has been recently established that transgenic mice overex-
pressingreticulon3developdystrophicneuriteswithimpair-
ment of spatial learning abilities and hippocampal long-
termpotentiation(LTP),thusresemblingAD-likephenotype
[85]. RTN-1C involvement in neurodegeneration processes
was also investigated by the use of a transgenic RTN-
1C mouse model. These mice exhibit maladaptive synaptic
plasticity and show disregulation of two plasticity-related
genes DARPP32 and NOS2a whose induction/correct mod-
ulation is required for normal expression of bidirectional
plasticity [86, 87]. Interestingly, Meyer-Lindenberg et al.
[88] identiﬁed a speciﬁc haplotype of DARPP32 gene, asso-
ciated with the risk for schizophrenia in a family-based asso-
ciation analysis. Altogether, these data highlight an as yet un-
known role for RTN-1C for the regulation of higher brain
functions associated with motor learning.
Reticulons have recently been implicated in other impor-
tant neurodegenerative disorders; amyotrophic lateral scle-
rosis, which is a rapidly progressing fatal neurodegenerative
disease, is characterized by the presence of protein inclusion
in motor neurons. The induction of ER-stress-mediated
apoptosis has proved to be an important event in the patho-
genesis of ASL; moreover ER occurs early in the disease and
involves the upregulation of protein disulphide isomerase
(PDI), an important endoplasmic reticulum chaperone [89].
Endoplasmic reticulum is the primary site for synthesis
and folding of secreted and membrane-bound proteins. The
accumulation of unfolded and misfolded proteins in ER
triggers a wide range of human neurodegenerative disorders.
It is now evident that molecules that regulate the ER
stress response represent potential candidates as drug targets
to tackle these diseases. Protein disulphide isomerase is a
chaperone involved in ER stress pathway, its activity being an
important cellular defence against protein misfolding. The
regulation of PDI activity may be a way of modulating ER
stressresponsesandconsequentlythebalancebetweenapop-
tosis or survival in stressed cells. An increase of PDI activity6 International Journal of Cell Biology
Table 1: Correlation between some RTNs cellular functions and their potential involvement in diﬀerent human diseases.
Cellular functions Human diseases
ER homeostasis Cancer and neurodegenerative disorders (i.e., ALS, Alzheimer’s disease)
Calcium homeostasis Neuronal pathologies (i.e., schizophrenia)
Apoptotic response Cancer, neurodegenerative disorders (i.e., ALS, Alzheimer’s disease Parkinson’s disease)
Membrane traﬃcking Neurodegenerative disorders (i.e., Parkinson’s disease)
Autophagy Cancer, neurodegenerative disorders (i.e., prion disease, Alzheimer’s disease, Huntington’s disease)
could represent a means of counteracting protein inclusion
formation typical in neurodegenerative diseases [90].
Several reports suggested that PDI function is particu-
larly important for neuronal cell death because it is able to
attenuate the neurotoxicity associated with the accumulation
of aggregated proteins which is responsible for neurode-
generative processes [90]. It has been suggested that PDI
activity is impaired in ALS. In addition anti-PDI-antibody
immunopositive inclusions have been found in neuroﬁbril-
lary tangles (NFTs) of the brain of Alzheimer’s patients [91].
Interestingly, a very recent paper has shown that the
reticulon family proteins, and in particular RTN-1C, rep-
resent novel regulators of PDI intracellular localization and
that this phenomenon could be an important modulating
factor in amyotrophic lateral sclerosis [92]. In this context,
recent data (manuscript submitted) have demonstrated that
the reticulon-1C family member is able to cause a dramatic
intracellular PDI redistribution, from a diﬀuse to a punctate
pattern which is not simply the result of ER stress induc-
tion. More importantly, RTN1-C signiﬁcantly increases PDI
enzymatic activity by modulating S-nitrosylation reactions
(Figure 2). These results are in line with previously known
experimentalevidencethatPDIfunctionalactivities(chaper-
oneandisomerase)areregulatedbyS-nitrosylationprocesses
[90]. Interestingly, it has been reported that inhibition of
PDI activity by S-nitrosylation is strongly associated with
mutant Cu/Zn superoxide dismutase toxicity in amyotrophic
lateral sclerosis disease and that a small molecule mimicking
the PDI active site protects against mutant superoxide
dismutase 1 inclusion formation [89]. Moreover in models
ofParkinson’sdisease,oneoftheS-nitrosylatedtargetsfound
is the PDI [90]. Thus, based on these ﬁndings, RTN-1C is a
goodpotential candidate forthe modulationofPDIfunction
inamelioratingaggregationandtoxicityofmutatedproteins.
Another interesting link between neurodegenerative dis-
ease and reticulons concerns the latter’s previously men-
tioned involvement in autophagic signaling pathway. Auto-
phagy dysfunction has been extensively described in neu-
rodegenerative conditions linked to protein misfolding and
aggregation [93]. Pharmacological induction of autophagy
can enhance the clearance of intracytoplasmic aggregate-
prone proteins, such as mutant forms of huntingtin, and
ameliorate pathology in cell and animal models of neurode-
generative diseases [94].
Recent studies have reported that autophagy is the
major degradational pathway following UPR activation in
neuronal cells and constitutes a connection between UPR
activation and autophagic pathology in AD brain [95]. In
line with this assumption, a recent work has reported that
RTN3 negatively regulates autophagy blocking the clearance
of cyPrP aggregates and thus providing a clue regarding
the potential for inducing autophagy for the treatment of
prion disease and other neurodegenerative diseases such as
Parkinson’s disease, Alzheimer’s disease, and Huntington’s
disease.
We have recently found that (manuscript submit-
ted) RTN-1C induces the activation of a Ca2+-dependent
autophagic pathway which is paralleled by changes in mito-
chondrial morphology and mitochondrial ﬁssion and fusion
machinery. RTN-1C-mediated ER stress condition not only
triggers alterations in Ca2+ homeostasis and mitochondrial
dynamics, but is also capable of inducing an autophagic
response. In the context of neurodegeneration, autophagy
may constitute a prosurvival mechanism in response to ER
stress and the accumulation of unfolded or misfolded pro-
teins; reticulon-1C structural ER protein may modulate the
neuronalstressatthebasisofneurodegenerativepathologies.
Finally very interesting recent work has reported that
reticulons are implicated in axonopathy and, in particular, in
hereditary spastic paraplegias (HSPs), a group of genetically
heterogeneous neurodegenerative conditions. Speciﬁcally
RTN-2 has been found to be mutated by a complete deletion
or a frameshift mutation, producing a truncated protein
which is the cause of HSP [96]. These ﬁndings are most
likely correlated to an abnormal reticulon function in the
morphogenesis of the ER resulting in axonal degeneration.
5. Conclusion
Reticulons are a family of integral membrane proteins impli-
cated in a variety of important biological functions such as
ER morphology and organization, nuclear envelope forma-
tion,calciumhomeostasis,andcelldeath.Inthelastfewyears
many experimental data have expanded the reticulons’ func-
tions to a wide array essential for neuronal cell homeostasis
Table 1. RTNs deregulations have been implicated in several
human diseases such as cancer development and/or neu-
rodegenerative disorders. However, for most of the reticulon
proteins the speciﬁc role and the biochemical mechanisms at
the basis of their biological function are still unknown.
Studies from our group have focused on the reticulon-
1C isoform of RTN1 gene which we originally identiﬁed as a
GCS interacting protein. Considering the role of this enzyme
in the mechanism of cancer development and MDR, we
have been interested in characterizing the role of RTN-1C in
tumour cells of neuroectodermal origin. During the last fewInternational Journal of Cell Biology 7
years, we have obtained a series of very interesting results in
theﬁeldofcancerdevelopment:theseindicatethatreticulon-
1C is a promising molecular target for novel therapeutic
approaches. We next expanded RTN-1C function to the
modulation of neurodegeneration processes. We discovered
t h a ti tp a r t i c i p a t e si nd i ﬀerent signaling pathways, from
ER-stress-induced cell death to autophagy, through the
regulation of diﬀerent enzymes such as HDACs or PDIs;
future studies however would need to deﬁne the molecular
details regulating the RTN-1C biological functions essential
for clarifying its involvement in neural cell pathologies.
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